A critical review of the pharmacological treatment of REM sleep behavior disorder in adults: time for more and larger randomized placebo-controlled trials.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing uncontrolled observational reports and small trials without formal systematic review methodology
PubMed 33410930 · doi:10.1007/s00415-020-10353-0
What was done
The authors critically reviewed published clinical and scientific evidence on pharmacological management of REM sleep behavior disorder (RBD) in adults aged over 50. They amalgamated published clinical observations for first-line treatments (clonazepam and melatonin) and evaluated findings from available randomized placebo-controlled trials.
What was found
Amalgamated clinical observations showed that 66.7% of 1,026 RBD patients reported improvement from clonazepam, and 32.9% of 137 RBD patients reported improvement from melatonin across various published outcome measures. However, three relatively small randomized placebo-controlled trials did not find either agent to be superior to placebo.
Why it matters
Clonazepam and melatonin are standard first-line therapies for RBD, but the lack of demonstrated efficacy in randomized controlled trials challenges common clinical assumptions and indicates an urgent need for larger trials.
Limits
The observational data reflect uncontrolled reports using heterogeneous outcome measures. The abstract does not report exact sample sizes, effect sizes, or statistical metrics for the three randomized trials, nor does it specify formal systematic review search criteria.
Cited by
- context Melatonin is an effective clinical treatment for REM sleep behavior disorder.